Financial Survey: Emergent Biosolutions (EBS) and Its Competitors
Emergent Biosolutions (NYSE: EBS) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Emergent Biosolutions to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares Emergent Biosolutions and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Emergent Biosolutions||$512.21 million||$159.99 million||25.94|
|Emergent Biosolutions Competitors||$7.86 billion||$2.50 billion||1.27|
Emergent Biosolutions’ peers have higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and price targets for Emergent Biosolutions and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Emergent Biosolutions Competitors||943||3779||5990||164||2.49|
Emergent Biosolutions presently has a consensus price target of $44.00, suggesting a potential upside of 16.19%. As a group, “Pharmaceuticals” companies have a potential upside of 26.71%. Given Emergent Biosolutions’ peers higher probable upside, analysts clearly believe Emergent Biosolutions has less favorable growth aspects than its peers.
This table compares Emergent Biosolutions and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Emergent Biosolutions Competitors||-3,613.41%||-52.33%||-8.32%|
Institutional & Insider Ownership
85.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 16.5% of Emergent Biosolutions shares are owned by insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Emergent Biosolutions has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Emergent Biosolutions’ peers have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.
Emergent Biosolutions beats its peers on 9 of the 13 factors compared.
About Emergent Biosolutions
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.